These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 26721202)

  • 1. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
    Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
    Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
    Dzieran J; Beck JF; Sonnemann J
    Cancer Sci; 2008 Aug; 99(8):1685-92. PubMed ID: 18754884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma.
    Ozyerli-Goknar E; Sur-Erdem I; Seker F; Cingöz A; Kayabolen A; Kahya-Yesil Z; Uyulur F; Gezen M; Tolay N; Erman B; Gönen M; Dunford J; Oppermann U; Bagci-Onder T
    Cell Death Dis; 2019 Nov; 10(12):894. PubMed ID: 31772153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.
    Cingöz A; Ozyerli-Goknar E; Morova T; Seker-Polat F; Esai Selvan M; Gümüş ZH; Bhere D; Shah K; Solaroglu I; Bagci-Onder T
    Oncogene; 2021 May; 40(18):3201-3216. PubMed ID: 33767436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer.
    Lopez-Campistrous A; Adewuyi EE; Benesch MGK; Ko YM; Lai R; Thiesen A; Dewald J; Wang P; Chu K; Ghosh S; Williams DC; Vos LJ; Brindley DN; McMullen TPW
    EBioMedicine; 2016 Oct; 12():86-97. PubMed ID: 27682510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression.
    Chen Z; Wu FF; Li J; Dong JB; He HY; Li XF; Lu Q; Zhang WX; Shao CM; Yao ZN; Lin N; Ye ZM; Xu JT; Li HY
    Phytomedicine; 2024 Apr; 126():155459. PubMed ID: 38417243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines.
    Calzolari A; Saulle E; De Angelis ML; Pasquini L; Boe A; Pelacchi F; Ricci-Vitiani L; Baiocchi M; Testa U
    PLoS One; 2014; 9(4):e94438. PubMed ID: 24740347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Nrf2 to treat thyroid cancer.
    Gong Z; Xue L; Li H; Fan S; van Hasselt CA; Li D; Zeng X; Tong MCF; Chen GG
    Biomed Pharmacother; 2024 Apr; 173():116324. PubMed ID: 38422655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
    Stieglmaier J; Bremer E; Kellner C; Liebig TM; ten Cate B; Peipp M; Schulze-Koops H; Pfeiffer M; Bühring HJ; Greil J; Oduncu F; Emmerich B; Fey GH; Helfrich W
    Cancer Immunol Immunother; 2008 Feb; 57(2):233-46. PubMed ID: 17665197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL acts synergistically with iron oxide nanocluster-mediated magneto- and photothermia.
    Belkahla H; Mazarío E; Sangnier AP; Lomas JS; Gharbi T; Ammar S; Micheau O; Wilhelm C; Hémadi M
    Theranostics; 2019; 9(20):5924-5936. PubMed ID: 31534529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical time window for the survival of neural progenitor cells by HDAC inhibitors in the hippocampus.
    Kim BW; Yang S; Lee CH; Son H
    Mol Cells; 2011 Feb; 31(2):159-64. PubMed ID: 21191817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.
    Xiang C; Zhang ML; Zhao QZ; Xie QP; Yan HC; Yu X; Wang P; Wang Y
    Oncotarget; 2017 Apr; 8(14):22954-22967. PubMed ID: 28086241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer.
    Kim Y; Yun HJ; Choi KH; Kim CW; Lee JH; Weicker R; Kim SM; Park KC
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid radiosensitizes anaplastic thyroid cells through a decrease of the DNA damage repair capacity.
    Perona M; Ibañez IL; Thomasz L; Villaverde MS; Oglio R; Rosemblit C; Grissi C; Campos-Haedo M; Dagrosa MA; Cremaschi G; Durán HA; Juvenal GJ
    J Endocrinol Invest; 2023 Nov; 46(11):2353-2365. PubMed ID: 37052871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mannose impairs tumour growth and enhances chemotherapy.
    Gonzalez PS; O'Prey J; Cardaci S; Barthet VJA; Sakamaki JI; Beaumatin F; Roseweir A; Gay DM; Mackay G; Malviya G; Kania E; Ritchie S; Baudot AD; Zunino B; Mrowinska A; Nixon C; Ennis D; Hoyle A; Millan D; McNeish IA; Sansom OJ; Edwards J; Ryan KM
    Nature; 2018 Nov; 563(7733):719-723. PubMed ID: 30464341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers.
    Montinaro A; Areso Zubiaur I; Saggau J; Kretz AL; Ferreira RMM; Hassan O; Kitzig E; Müller I; El-Bahrawy MA; von Karstedt S; Kulms D; Liccardi G; Lemke J; Walczak H
    Cell Death Differ; 2022 Mar; 29(3):492-503. PubMed ID: 34535764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different extracts of curcumin on TPC1 papillary thyroid cancer cell line.
    Perna A; De Luca A; Adelfi L; Pasquale T; Varriale B; Esposito T
    BMC Complement Altern Med; 2018 Feb; 18(1):63. PubMed ID: 29448931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIAL-based combination therapies in cancers.
    Deng Q; Chen L; Zhang G; Liu L; Luo SM; Gao X
    Int Immunopharmacol; 2024 Jul; 138():112570. PubMed ID: 38971105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular underpinnings of HDAC inhibition revealed.
    Adams CM; Eischen CM
    Cell Cycle; 2016 Aug; 15(15):1943-4. PubMed ID: 27153392
    [No Abstract]   [Full Text] [Related]  

  • 20. Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells.
    Li H; Zhang Z; Gao C; Wu S; Duan Q; Wu H; Wang C; Shen Q; Yin T
    Cell Biosci; 2023 Nov; 13(1):206. PubMed ID: 37951908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.